Hinge Health is a digital physiotherapy leader with strong technology. Outcomes data shows that 68% pain reduction for patients, and 2.4x ROI for employers. Hinge's competitive edge is the largest dataset, no need for sensors, and integrated pain management. My base case DCF model values HNGE at $43/share (1-year) and $60-$80/share (5-years), with upside from Medicare/Medicaid and international expansion.
Hinge Health's IPO impressed with strong demand, rapid growth, and early profitability, reflecting investor enthusiasm for tech-driven healthcare solutions. The company targets the large MSK market, using AI and wearables to automate physical therapy, improve outcomes, and reduce costs for employers and patients. Valuation is rich at 5.5x sales and 60x earnings, but accelerating revenue growth and recent operating profits justify optimism despite competition and concentration risks.